Associated Papers
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Bazhenova L et al.
Clinical Lung Cancer, 2025
Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients.
Li W et al.
Cancers, 2025
Diverse Resistant Mechanisms Identified Using Serial Next-Generation Sequencing in a Patient With ALK-Rearranged Metastatic Lung Adenocarcinoma: A Case Report.
Saw SPL et al.
Jto Clinical and Research Reports, 2023
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A et al.
Nature Cancer, 2022
Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Steeghs EMP et al.
Lung Cancer (amsterdam, Netherlands), 2022
Genomic profiles of Indonesian colorectal cancer patients.
Abdullah M et al.
F1000research, 2022
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.
Christopoulos P et al.
Translational Lung Cancer Research, 2021
34164264 (PubMed )
Supplement: tlcr-10-05-2118-supplementary.pdf
Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Dietz S et al.
Ebiomedicine, 2020
33161228 (PubMed )
Supplement: mmc1.pdf
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Select a paper to view details